Previous Pause Next
Home >> News Center >>
Clinical Trials
Clinical Conductor Site Clinical Trial Management System (CTMS) Improves Clinical Trial Productivity at Research Sites PDF Print E-mail
Friday, 27 March 2009 10:30
Bio-Optronics, Inc., a leader in healthcare workflow software, announces that its Clinical Conductor Site Clinical Trial Management System (CTMS) continues to improve productivity for investigative clinical research sites, particularly in the areas of patient recruitment, advertising ROI, scheduling, and financial management.
Intensively Lowering Blood Glucose In Critically Ill Patients Increases the Risk of Death PDF Print E-mail
Friday, 27 March 2009 10:18
The current practice of intensively lowering blood glucose in critically ill patients increases the risk of death by 10%. Results of the largest trial of intensive glucose lowering in critically ill patients published in The New England Journal of Medicine indicate that international clinical guidelines need urgent review.
First Phase III Study of Vilazodone in Treatment of Major Depressive Disorder PDF Print E-mail
Saturday, 14 March 2009 17:49
Clinical Data, Inc. (NASDAQ: CLDA) announced the publication of the complete results from its first pivotal Phase III study of vilazodone as a potential treatment for major depressive disorder in the Journal of Clinical Psychiatry (JCP). Vilazodone, if approved, could represents a new class of drugs for the treatment of depression, due to its novel dual mechanism of action as both a selective serotonin reuptake inhibitor (SSRI) and a 5HT1A partial agonist.
Ariad's Partner Merck Initiates Phase II Lung Cancer Trial PDF Print E-mail
Wednesday, 11 March 2009 16:42

Ariad Pharmaceuticals, a developer of small-molecule drugs to treat cancer, has announced the initiation by Merck & Co, of a Phase II clinical trial to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced non-small cell lung cancer.

American Oriental Bioengineering to Initiate a Phase One Clinical Trial in The United States of AOBO-001 Oral Capsule PDF Print E-mail
Tuesday, 10 March 2009 22:18
American Oriental Bioengineering, Inc. (NYSE: AOB), a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, announced that the Company is initiating a phase one clinical trial of AOBO-001, an oral capsule developed from traditional Chinese herbal medicine for the treatment of urinary incontinence (UI) in the United States.
Combating Weight Gain Caused by Antipsychotic Treatments PDF Print E-mail
Friday, 27 March 2009 10:26

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia. Unfortunately, the weight gain commonly experienced with antipsychotic treatment is an important side effect for many patients, and causes many patients to discontinue their use leading to even further problems.

Vaccine to Prevent Colon Cancer Being Tested in Patients PDF Print E-mail
Wednesday, 25 March 2009 14:17

Researchers at the University of Pittsburgh School of Medicine have begun testing a vaccine that might be able to prevent colon cancer in people at high risk for developing the disease. If shown to be effective, it might spare patients the risk and inconvenience of repeated invasive surveillance tests, such as colonoscopy, that are now necessary to spot and remove precancerous polyps.

Success of Pfizer Pancreatic Cancer Drug Stops Trial PDF Print E-mail
Saturday, 14 March 2009 17:00
Global drug company Pfizer Inc announced yesterday, 12 March, that a phase 3 clinical trial of its pancreatic cancer drug Sutent (sunitinib malate) stopped early because the drug showed significant benefits in patients.
pSivida Completes Enrollment in Pancreatic Cancer Trial PDF Print E-mail
Wednesday, 11 March 2009 16:28

pSivida, a drug delivery company, has completed enrollment of the BrachySil dose ranging clinical trial.

Long-Term Effects of Early Parkinson's Treatments Similar PDF Print E-mail
Tuesday, 10 March 2009 22:02
A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.
<< Start < Prev 121 122 Next > End >>

Page 122 of 122